Biotechnology Assets Equity 2024

Biotechnology Assets Aktienanalyse

What does Biotechnology Assets do?

ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Biotechnology Assets's Equity

Biotechnology Assets's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biotechnology Assets's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biotechnology Assets's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biotechnology Assets's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biotechnology Assets’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biotechnology Assets Stock

What is the equity of Biotechnology Assets this year?

Biotechnology Assets has equity of 6.68 M EUR this year.

What was the equity of Biotechnology Assets compared to the previous year?

The equity of Biotechnology Assets has increased/decreased by 65.84% increased compared to the previous year.

What impact does a high equity have on investors of Biotechnology Assets?

A high equity is advantageous for investors of Biotechnology Assets as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Biotechnology Assets?

A low equity can be a risk for investors of Biotechnology Assets, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Biotechnology Assets affect the company?

An increase in equity of Biotechnology Assets can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Biotechnology Assets affect the company?

A reduction in equity of Biotechnology Assets can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Biotechnology Assets?

Some factors that can affect the equity of Biotechnology Assets include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Biotechnology Assets so important for investors?

The equity of Biotechnology Assets is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Biotechnology Assets take to change the equity?

To change equity, Biotechnology Assets can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Biotechnology Assets pay?

Over the past 12 months, Biotechnology Assets paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biotechnology Assets is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biotechnology Assets?

The current dividend yield of Biotechnology Assets is .

When does Biotechnology Assets pay dividends?

Biotechnology Assets pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biotechnology Assets?

Biotechnology Assets paid dividends every year for the past 0 years.

What is the dividend of Biotechnology Assets?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biotechnology Assets located?

Biotechnology Assets is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biotechnology Assets kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biotechnology Assets from 7/1/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Biotechnology Assets pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Biotechnology Assets in the year 2023?

In the year 2023, Biotechnology Assets distributed 0 EUR as dividends.

In which currency does Biotechnology Assets pay out the dividend?

The dividends of Biotechnology Assets are distributed in EUR.